Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...3940414243444546474849...5960»
  • ||||||||||  Sandostatin (octreotide acetate solution for injection) / Novartis
    [VIRTUAL] A Case of Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone (GHRH) Secretion from a Bronchial Neuroendocrine Tumour () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2415;    
    She was treated with intramuscular sandostatin 20mg q28days and then underwent a left pneumonectomy, resulting in biochemical resolution of her acromegaly (IGF-1 219 μg/L)...Learning points Diagnosis of acromegaly due to ectopic GHRH secretion requires high clinical suspicion by the treating clinicians (e.g., endocrinologist, oncologist) as well as review of histology by expert pathologists. Our case highlights that ectopic GHRH secretion is a rare but important cause of acromegaly, which should always be suspected when a clear pituitary cause is not identified.
  • ||||||||||  [VIRTUAL] A Mysterious Multiple Endocrine Neoplasia (MEN) Like Syndrome () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2348;    
    The biochemical phenotype of pheochromocytoma (elevated metanephrines) is consistent with cluster 2 tumors of kinase signaling pathway as seen in tumors of MEN syndrome and neurofibromatosis. We hope to gain more insight via whole exome sequencing to evaluate for potential novel gene mutation(s).
  • ||||||||||  [VIRTUAL] Evaluation of Arterial Stiffness in Acromegaly Patients () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1516;    
    Acromegaly is associated with increased morbidity and mortality primarily attributed to cardiovascular problems. We thought that it may be a guiding method in disease management since it can be an early marker of cardiovascular risk.
  • ||||||||||  [VIRTUAL] Factors Associated with Remission After Surgery for Acromegaly () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1490;    
    Therefore, in such acromegaly patients close monitoring of glucose status is recommended during treatment. In our study, predictors of biochemical remission after surgery were smaller tumor size, lower Knosp grade, and lower preoperative GH and IGF-1 levels.
  • ||||||||||  cabergoline / Generic mfg., Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    [VIRTUAL] Pituitary Magnetic Resonance Imaging in the Postoperative Follow-Up of Patients with Acromegaly, Less Is More! () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1488;    
    Current guidelines for MRI surveillance recommend 12 week post-operative (postop) imaging for all pts and yearly if on pegvisomant (PEG)...55 pts were on PIT-directed therapy (50 on somatostatin receptor ligands (SRL) alone, 1 on cabergoline (Cab) alone, 4 on SRL/Cab), 12 on PEG > 1 year (9 on PEG alone.) 11/83 (13.25%) had tumor growth at median 3.5 years (range 1-11)...Conversely, pts with residual adenoma not on medical therapy should be closely monitored biochemically and by serial MRIs. Further studies are needed to identify appropriate imaging interval for pts on medications and based on characteristics of aggression (such as sparsely granulated, large residual tumors, lack of biochemical control despite medications).
  • ||||||||||  [VIRTUAL] The Prevalence of Acromegaly in the Sleep Apnoea Clinic () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1482;    
    As a consequence of the significant number of patients with elevated serum IGF-1 measurements requiring further investigation, IGF-I is not currently a cost-effective screening tool for early detection of acromegaly in OSA patients. Funding: Ipsen UK
  • ||||||||||  [VIRTUAL] AIP Gene Germline Mutations in Non-Selected Patients with Apparently Sporadic Pituitary Macrodenomas () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1480;    
    In our series of apparently sporadic pituitary macroadenomas, AIP gene mutation carriers did not differ substantially from patients with negative genetic testing. A risk factor-centered approach to AIP genetic screening may result in missing germline mutations, therefore, there is a need to establish if such a situation negatively impacts a patient’s and his/her family outcomes.
  • ||||||||||  [VIRTUAL] IGF-1 in the Early Post-operative Assessment of Acromegaly () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1478;    
    In the vast majority of patients, 6 weeks post-operative IGF-1 can be used to assess response to surgery avoiding a delay in treatment. However, we would recommend repeating IGF-1 levels at 3–6 months in those who have marginally elevated IGF-1 above normal (≤ 1.12), without cavernous sinus invasion and a post-operative GH of <1 ng/mL prior to intervening if the IGF-1 is elevated 6 weeks as the IGF-1 may normalize.
  • ||||||||||  [VIRTUAL] IGF-1 Levels During Normal Pregnancy () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1464;    
    1Frankenne et al (1988). The physiology of growth hormones in pregnant women and partial characterization of the placental GH variant.
  • ||||||||||  hydrocortisone / Generic mfg.
    [VIRTUAL] Factors Associated With QoL Impairment In Patients With Acromegaly In The Elderly () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1450;    
    In total, current medical therapy and hydrocortisone replacement were associated with lower QoL scale as previously reported; however, when stratified by age, arthropathy and high BMI were associated with lower QoL scale in the elderly. These data clearly indicate that the factors influence on QoL are different depending on the age.
  • ||||||||||  aripiprazole / Generic mfg.
    [VIRTUAL] Pituitary Tumor Apoplexy Presenting with Acute Psychosis () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1435;    
    Repeated PRL was 31,6 ng/dl after changing psychiatric treatment to aripiprazole... Psychiatric symptoms can be the first manifestation of PT, so atypical presentations should warrant further workup with brain imaging.
  • ||||||||||  Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
    [VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1360;    
    Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
  • ||||||||||  [VIRTUAL] Age-Associated Local GH Promotes Colon Neoplasia () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1314;    
    Suppression of GH in these aging organoids led to increased phospho-p53 and reduced DNA damage. Although somatotroph axis endocrine activity decreases with age, local GH induced in response to age-related DNA damage may trigger a “field change,” creating a milieu favorable for colon neoplastic development.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    [VIRTUAL] Generation of a Long-Acting Human Growth Hormone Receptor Antagonist by Site-Specific Pegylation () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1294;    
    Pegvisomant is the only GHR antagonist approved for clinical use...Subcutaneous administration of the PEG-30kDa conjugate (10 mg/kg/day) reduced serum IGF-I levels in mice. In conclusion, we have generated a novel long-acting human GHR antagonist conjugate by introducing a free cysteine at a non-essential site of the antagonist and targeted attachment of PEG.
  • ||||||||||  [VIRTUAL] Novel Genetic Variant of Carney Complex With Acromegaly () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1285;    
    The diagnosis has many deleterious consequences if not treated early. Additionally, this case represents a novel pathologic variant of PRKAR1A that has not previously been identified in Carney complex.
  • ||||||||||  bisoprolol / Generic mfg., Mitsubishi Tanabe, EMD Serono
    [VIRTUAL] Co-Secreting TSH and Growth Hormone Pituitary Adenoma () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1278;    
    He had ablation twice and was started on bisoprolol and anticoagulant...This is effective in about 90% of patients with TSH secreting pituitary adenomas TSHoma should be differentiated from resistance to thyroid (RTH). The main difference between TSHoma and RTH is the presence of signs and symptoms of hyperthyroidism in patients with TSHoma, absence of a family history, normal thyroid hormone levels in family members, and the presence of an elevated glycoprotein α-subunit in patients with pituitary tumor.
  • ||||||||||  Signifor LAR (pasireotide) / Novartis
    [VIRTUAL] Pregnancy in Acromegaly: Report of Five Cases () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1270;    
    From our experience, patients with acromegaly may have normal babies, even in patients with uncontrolled hypersecretion and lack of medical treatment during pregnancy. The consensus is, however, that there is no indication to use medication to control GH hypersecretion or tumor size in acromegaly patients during pregnancy (1).